Artificial Intelligence (AI) in Medical Writing Market Report 2024

The artificial intelligence (AI) in medical writing market size has grown rapidly in recent years. It will grow from $0.79 billion in 2023 to $0.91 billion in 2024 at a compound annual growth rate (CAGR) of 15.2%. The growth during the historic period was driven by increased outsourcing to contract research organizations, higher costs associated with medical writing, impacts from trade agreements and government policies, greater complexity in regulatory approval processes, and heightened demand for precise and dependable medical content.

The artificial intelligence (AI) in medical writing market size is expected to see rapid growth in the next few years. It will grow to $1.62 billion in 2028 at a compound annual growth rate (CAGR) of 15.3%. Anticipated growth in the forecast period stems from a favorable environment for clinical studies, expanding adoption of telemedicine and remote healthcare services, enhanced digital infrastructure, rising recognition of AI's potential benefits in healthcare, and escalating demand for accurate and reliable medical content. Key trends expected in this period include advancements in natural language processing (NLP) and machine learning algorithms, increased adoption of machine learning (ML), the proliferation of digital health services, integration with emerging technologies, and advancements in clinical decision support systems.

The anticipated rise in demand for new pharmaceutical drugs and therapies is expected to drive growth in the medical writing market through the integration of artificial intelligence (AI). This growth is fueled by ongoing efforts to address unmet medical needs, combat drug resistance, and enhance patient outcomes with more innovative treatments. AI applications in medical writing within pharmaceutical and drug production sectors promise increased efficiency, accuracy, and innovation, contributing to the development of safer and more effective therapies for various medical conditions. For instance, as reported in June 2023 by the European Federation of Pharmaceutical Industries and Associations (EFPIA), pharmaceutical production in Europe reached $384.2 billion (€340,000 million) in 2022, marking a 4.95% increase from €323.95 billion in 2021. This surge in pharmaceutical demand underscores the role of AI in driving growth within the medical writing market.

Leading companies in the AI medical writing sector are focusing on integrating advanced features, such as AI-powered drafting, to optimize efficiency and precision in document creation and management for regulatory submissions and medical communications. AI-powered drafting leverages machine learning and natural language processing algorithms to automate initial document drafts or outlines, significantly streamlining content creation tasks. For instance, TrialAssure, a US-based pharmaceutical technology provider, launched TrialAssure LINK AI 2 in June 2024. This upgraded platform enables pharmaceutical and biotechnology firms, clinical research organizations, and service providers to efficiently generate a wide range of regulatory and medical writing documents using AI. The solution automates document creation from initial drafting through to final approval stages, enhancing the overall authoring process.

In March 2024, Indegene Limited, a US-based company specializing in life sciences commercialization, acquired Trilogy Writing & Consulting GmbH for an undisclosed sum. This acquisition bolstered Indegene’s capabilities in clinical and regulatory writing for global market authorization applications. Additionally, the acquisition deepened Indegene's commitment to content automation, particularly leveraging generative AI, to enhance outcomes for clients in clinical, regulatory writing, and related services. Trilogy Writing & Consulting GmbH, headquartered in Germany, provides medical writing and regulatory documentation services utilizing AI-based tools.

Major companies operating in the artificial intelligence (AI) in medical writing market are International Business Machines Corporation, IQVIA Holdings Inc., Icon PLC, Syneos Health Pvt Ltd, Parexel International Corporation, Veeva Systems, Cactus Communications, Tata Elxsi, Allucent Inc, Certara Inc, Freyr Solutions, Amplity Health, Indegen Limited, MMS Holdings Inc., Jasper AI Inc, Symbiance AI Inc, GenInvo Technologies Pvt. Ltd., Trilogy Writing & Consulting GmbH, Yseop S.A.S., Turacoz Healthcare Solution, Averbis GmbH, EMTEX Life Sciences, DeepCura AI, Dezzai Inc, Narrativa Inc.

North America was the largest region in the artificial intelligence (AI) in medical writing market in 2023. The regions covered in the artificial intelligence (AI) in medical writing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the artificial intelligence (AI) in medical writing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Artificial intelligence (AI) in medical writing involves the use of intelligent technologies to streamline and improve the creation of medical documents, such as research papers, clinical trial reports, regulatory submissions, patient information leaflets, and other healthcare-related content. AI enhances efficiency, accuracy, and accessibility in these tasks, thereby contributing to advancements in medical research and healthcare delivery.

The primary categories of AI in medical writing encompass clinical writing, typewriting, scientific writing, and various other applications. Clinical writing focuses on producing documents related to clinical trials and medical studies, including protocols, study reports, and informed consent forms that detail the procedures and outcomes of clinical research. AI applications extend to regulatory documentation, automated literature reviews, language translation, pharmacovigilance, and content modularization for end users in sectors such as medical devices, pharmaceuticals, biotechnology, and related fields.

The artificial intelligence (AI) in medical writing market research report is one of a series of new reports that provides artificial intelligence (AI) in medical writing market statistics, including artificial intelligence (AI) in medical writing industry global market size, regional shares, competitors with an artificial intelligence (AI) in medical writing market share, detailed artificial intelligence (AI) in medical writing market segments, market trends and opportunities, and any further data you may need to thrive in the artificial intelligence (AI) in medical writing industry. This artificial intelligence (AI) in medical writing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The artificial intelligence (AI) in medical writing market consists of revenues earned by entities by providing services such as automated content generation, proofreading and editing, regulatory compliance, and literature review. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in medical writing market also include sales of high-performance computers, graphics processing units, and storage devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.